■ Details :
 

1. Date of Occurrence : December 8, 2025

2. Company Name : InnoPharmax Inc.

3. Relationship to the Company (please specify parent company or subsidiary) : The Company

4. Reciprocal Shareholding Ratio : Not applicable

5. Cause of Occurrence :
Sapropterin Dihydrochloride Tablets of InnoPharmax Inc. have been licensed to Shandong New Era Pharmaceutical Co., Ltd. for commercialization in China under the brand name Haipuyi. The licensee has received approval from the National Healthcare Security Administration of China (NHSA) for inclusion of the product in the Commercial Health Insurance Innovative Drug List. The validity period is from January 1, 2026 to December 31, 2027.

6. Countermeasures : None.

7. Other Matters to be Stated : None.